| Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH). | |
| | |
MedLine Citation:
|
PMID: 21410684 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Benign prostatic hyperplasia (BPH) is the major cause of lower urinary tract symptoms in men aged 50 or older. Symptoms are not normally life threatening, but often drastically affect the quality of life. The number of men seeking treatment for BPH is expected to grow in the next few years as a result of the ageing male population. Estimates of annual pharmaceutical sales of BPH therapies range from $US 3 to 10 billion, yet this market is dominated by two drug classes. Current drugs are only effective in treating mild to moderate symptoms, yet despite this, no emerging contenders appear to be on the horizon. This is remarkable given the increasing number of patients with severe symptoms who are required to undergo invasive and unpleasant surgery. This review provides a brief background on prostate function and the pathophysiology of BPH, followed by a brief description of BPH epidemiology, the burden it places on society, and the current surgical and pharmaceutical therapies. The recent literature on emerging contenders to current therapies and novel drug targets is then reviewed, focusing on drug targets which are able to relax prostatic smooth muscle in a similar way to the α(1) -adrenoceptor antagonists, as this appears to be the most effective mechanism of action. Other mechanisms which may be of benefit are also discussed. It is concluded that recent basic research has revealed a number of novel drug targets such as muscarinic receptor or P2X-purinoceptor antagonists, which have the potential to produce more effective and safer drug treatments. |
| | |
Authors:
|
S Ventura; V l Oliver; C W White; J H Xie; J M Haynes; B Exintaris |
Related Documents
:
|
15493534 - Auditory evoked responses in a comparison between schizophrenia patients with and witho... 21203154 - 2-methoxy-phenyl 2-{2-[1-methyl-5-(4-methyl-benzo-yl)pyrrol-2-yl]acetamido}acetate. 7061724 - Hydrochlorothiazide pharmacokinetics and pharmacologic effect: the influence of indomet... 7871074 - Acute and residual effects of alcohol and marijuana, alone and in combination, on mood ... 18500564 - In vitro studies are sometimes better than conventional human pharmacokinetic in vivo s... 287334 - Intra-arterial chemotherapy of malignant head and neck tumours with superselective angi... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: British journal of pharmacology Volume: 163 ISSN: 1476-5381 ISO Abbreviation: Br. J. Pharmacol. Publication Date: 2011 Jul |
Date Detail:
|
Created Date: 2011-06-09 Completed Date: 2011-11-02 Revised Date: 2012-09-24 |
Medline Journal Info:
|
Nlm Unique ID: 7502536 Medline TA: Br J Pharmacol Country: England |
Other Details:
|
Languages: eng Pagination: 891-907 Citation Subset: IM |
Copyright Information:
|
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society. |
Affiliation:
|
Medicinal Chemistry and Drug Action, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia. Sab.Ventura@monash.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Drug Discovery* Humans Male Muscle Contraction / drug effects Muscle, Smooth / drug effects Prostatic Hyperplasia / drug therapy*, enzymology, metabolism*, physiopathology |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Analysis of the contribution of I(to) to repolarization in canine ventricular myocardium.
Next Document: Differential contributions of adenosine to hypoxia-evoked depressions of three neuronal pathways in ...